ArticleCureus2026
Short-Term Clinical Outcomes of Platelet-Rich Plasma Injections in Patients With Rotator Cuff Tendinopathy and Partial-Thickness Rotator Cuff Tears.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionPlatelet-rich plasma (PRP) has been increasingly applied for rotator cuff pathology; however, clinical evidence regarding its short-term efficacy remains limited. This study evaluated the effectiveness of a single PRP injection for rotator cuff injury.
methodsThis single-center retrospective study analyzed 25 cases managed between August 2024 and August 2025 to evaluate the effectiveness of a single PRP injection for rotator cuff injury. Pain was assessed using the visual analog scale (VAS), and shoulder function was assessed using Shoulder 36 (Version 1.3) at baseline and at one, two, and three months.
resultsMean VAS decreased from 7.48 at baseline to 4.76 at one month, 4.40 at two months, and 3.16 at three months, with significant improvements at all follow-up time points compared with baseline (paired t-test, p < 0.001). At three months, 20 of 25 cases (80.0%) achieved a VAS improvement of ≥2 points, and 16 of 25 cases (64.0%) achieved a ≥50% reduction from baseline. In the Shoulder 36, the domains of pain, range of motion, muscle strength, general health perception, and activities of daily living improved over time; pain and muscle strength improved significantly from one month, and range of motion, general health perception, and activities of daily living improved significantly at two and three months (all p < 0.05), whereas the sports ability domain did not reach statistical significance. No significant associations were observed between three-month improvements in VAS or Shoulder 36 and the interval from symptom onset to the first PRP injection, baseline Ultrasound Shoulder Pathology Rating Scale (USPRS) grade, or prior treatment (no treatment, hyaluronic acid, or corticosteroid). Retreatment was performed in six cases (24.0%), and PRP was selected in all cases; baseline characteristics and three-month VAS improvement did not differ significantly between cases with and without retreatment.
conclusionIn this single-center retrospective cohort of 25 cases, a single PRP injection was associated with significant improvements in VAS and multiple Shoulder36 domains over three months, and no apparent complications were observed during follow-up.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.